Show simple item record

dc.contributor.authorOzdemir, Yurday
dc.contributor.authorAkyol, Fadil
dc.contributor.authorOzyiğit, Gokhan
dc.contributor.authorHurmuz, Pervin
dc.contributor.authorOnal, Cem
dc.contributor.authorSelek, Ugur
dc.contributor.authorKarabulut, Erdem
dc.date.accessioned2019-11-27T12:48:08Z
dc.date.available2019-11-27T12:48:08Z
dc.date.issued2015
dc.identifier.issn1306-133X
dc.identifier.uri10.4999/uhod.15846
dc.identifier.urihttp://hdl.handle.net/11727/4267
dc.description.abstractThe aim of this study into evaluate the treatment results of three dimensional conformal radiotherapy (3DCRT) and androgen deprivation therapy (ADT) in patients with clinically localized prostate cancer (CLPC). Between June 1998 and December 2011, 577 patients with the diagnosis of CLPC were treated. ADT was started 3 months prior to radiotherapy (RT). 3DCRT was delivered to prostate and the seminal vesicles (SV) to a total dose of 70Gy. Additionally, patients with lymph node (LN) positivity received 50.4Gy RT to pelvic LN's. Median follow up time was 65 months. Five-ten years overall survival (OS), cause specific survival (CSS), PSA relapse-free survival (PSA-RFS) and distant metastasis-free survival (DMFS) rates were 92-74%, 97-91%, 77-55% and 94-88%, respectively. OS was negatively affected from LN positivity (p < 0.001). In the subgroup of patients With GS 8, there was no significant difference between < 1 years and 1 years of ADT in terms of CSS, PSA-RFS and DMFS. OS was better in patients with < 1 years of ADT (p = 0.01). Five year OS (p = 0.02), CSS (p = 0.05), PSA-RFS (p = 0.01) and DMFS (p = 0.07) rates were inferior in the high risk group patients that used ADT 1 year. Acute and late RTOG grade III/IV gastrointestinal system toxicity rates were 1.7% and 5% and acute and chronic RTOG grade III/IV genitourinary system toxicity rates were 1.4% and 5%, respectively. 3DCRT and ADT combination is an effective treatment modality with acceptable toxicities in patients with clinically localized prostate cancer.en_US
dc.language.isoengen_US
dc.relation.isversionof10.4999/uhod.15846en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProstate canceren_US
dc.subjectConformal radiotherapyen_US
dc.subjectAndrogen deprivation therapyen_US
dc.titleThree Dimensional Conformal Radiotherapy and Androgen Deprivation Therapy in Patients with Clinically Localized Prostate Cancer; Hacettepe University Experienceen_US
dc.typearticleen_US
dc.relation.journalUHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISIen_US
dc.identifier.volume25en_US
dc.identifier.issue2en_US
dc.identifier.startpage107en_US
dc.identifier.endpage111en_US
dc.identifier.wos000357440000005


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record